{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:26:05Z","timestamp":1758479165186,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["97-4-23-13222"],"award-info":[{"award-number":["97-4-23-13222"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Medications currently recommended for the treatment of Obsessive-Compulsive Disorder (OCD) usually relieve the severity of symptoms by as much as 20\u201330%, and satisfactory treatment is obtained in 40\u201360% of patients with OCD. Nevertheless, the remaining symptoms continue to impair the patients\u2019 function. Therefore, it is necessary to investigate possible strategies to improve the mitigation of symptoms. In this study, the main objective was to examine and investigate the effectiveness of granisetron, which is a serotonin 5-hydroxytryptamine receptor type 3 (5-HT<jats:sub>3<\/jats:sub>) antagonist, as an adjunct therapy to selective serotonin reuptake inhibitors, for the purpose of ameliorating OCD symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>fifty-eight patients diagnosed with OCD, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, who had a Yale-Brown obsessive-compulsive scale (Y-BOCS) score of more than 21 were recruited in a double-blinded, parallel-group, placebo-controlled, clinical trial of 10 weeks to receive either granisetron (1\u00a0mg twice daily) and sertraline (100\u00a0mg daily initially followed by 200\u00a0mg daily after week 4) or placebo and sertraline. The primary outcome was OCD symptoms measured by the Y-BOCS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Y-BOCS total score significantly dropped in both groups (28.9 to 17.7 for granisetron plus sertraline and 27.5 to 19.3 for placebo plus sertraline group with a slightly greater drop for granisetron plus sertraline group), while the granisetron plus sertraline group experienced a significantly greater reduction in obsession scores (Greenhouse-Geisser F(2.32,97.57)\u2009=\u20094.52,p-value\u2009=\u20090.01). Moreover, in comparison with the placebo plus sertraline group, the proportion of the patients showing complete response was considerably higher among the granisetron plus sertraline group (<jats:italic>P<\/jats:italic>-value\u2009&lt;\u20090.01). No major adverse effects were observed in any of the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results suggest that granisetron augmentation of sertraline may increase the rate of response in patients with moderate to severe non-refractory OCD. Further studies are suggested in this regard.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-022-00610-5","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T18:03:59Z","timestamp":1664301839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Ala","family":"Ghobadian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnam","family":"Shariati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Kamalzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Shati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Eftekhar Ardebili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoomeh","family":"Yarahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Shalbafan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"issue":"12","key":"610_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/archpsyc.1988.01800360042006","volume":"45","author":"M Karno","year":"1988","unstructured":"Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45(12):1094\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"610_CR2","doi-asserted-by":"crossref","unstructured":"Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T. Epidemiology of obsessive-compulsive disorder: A world view. The Journal of clinical psychiatry. 1997.","DOI":"10.1159\/000061358"},{"issue":"13","key":"610_CR3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2017.2200","volume":"317","author":"ME Hirschtritt","year":"2017","unstructured":"Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 2017;317(13):1358\u201367.","journal-title":"JAMA"},{"issue":"1","key":"610_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00787-012-0357-7","volume":"22","author":"PH Thomsen","year":"2013","unstructured":"Thomsen PH. Obsessive\u2013compulsive disorders. Eur Child Adolesc Psychiatry. 2013;22(1):23\u20138.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"2","key":"610_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.comppsych.2009.03.004","volume":"51","author":"U Albert","year":"2010","unstructured":"Albert U, Maina G, Bogetto F, Chiarle A, Mataix-Cols D. Clinical predictors of health-related quality of life in obsessive-compulsive disorder. Compr Psychiatr. 2010;51(2):193\u2013200.","journal-title":"Compr Psychiatr"},{"issue":"4","key":"610_CR6","first-page":"102","volume":"8","author":"RL DuPont","year":"1995","unstructured":"DuPont RL, Rice D, Shiraki S, Rowland C. Economic costs of obsessive-compulsive disorder. Med interface. 1995;8(4):102\u20139.","journal-title":"Med interface"},{"key":"610_CR7","doi-asserted-by":"crossref","unstructured":"Seibell PJ, Hollander E. Management of obsessive-compulsive disorder. F1000prime reports. 2014;6.","DOI":"10.12703\/P6-68"},{"issue":"1","key":"610_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","volume":"162","author":"EB Foa","year":"2005","unstructured":"Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(1):151\u201361.","journal-title":"Am J Psychiatry"},{"key":"610_CR9","doi-asserted-by":"crossref","unstructured":"Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. The Journal of clinical psychiatry. 1999.","DOI":"10.4088\/JCP.v60n0206"},{"issue":"5","key":"610_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/00004714-200110000-00006","volume":"21","author":"S Erzegovesi","year":"2001","unstructured":"Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol. 2001;21(5):488\u201392.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"610_CR11","doi-asserted-by":"publisher","first-page":"e2584","DOI":"10.1002\/hup.2584","volume":"32","author":"S Arabzadeh","year":"2017","unstructured":"Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z, et al. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double\u2010blind study. Hum Psychopharmacology: Clin Experimental. 2017;32(4):e2584.","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"issue":"11","key":"610_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1177\/0269881119878177","volume":"33","author":"M Shalbafan","year":"2019","unstructured":"Shalbafan M, Malekpour F, Tadayon Najafabadi B, Ghamari K, Dastgheib S-A, Mowla A, et al. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. J Psychopharmacol. 2019;33(11):1407\u201314.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"610_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1634\/theoncologist.9-6-673","volume":"9","author":"M Aapro","year":"2004","unstructured":"Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist. 2004;9(6):673\u201386.","journal-title":"Oncologist"},{"issue":"3","key":"610_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.pharmthera.2011.02.003","volume":"130","author":"TK Machu","year":"2011","unstructured":"Machu TK. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol Ther. 2011;130(3):338\u201347.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"610_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2165\/11635850-000000000-00000","volume":"26","author":"N Askari","year":"2012","unstructured":"Askari N, Moin M, Sanati M, Tajdini M, Modabbernia A, Najand B, et al. Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder. CNS Drugs. 2012;26(10):883\u201392.","journal-title":"CNS Drugs"},{"issue":"6","key":"610_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YIC.0000000000000043","volume":"29","author":"M Heidari","year":"2014","unstructured":"Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, et al. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive\u2013compulsive disorder. Int Clin Psychopharmacol. 2014;29(6):344\u201350.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"610_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.euroneuro.2013.12.003","volume":"24","author":"S Pallanti","year":"2014","unstructured":"Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol. 2014;24(3):375\u201380.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"610_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/hup.2461","volume":"30","author":"D Serata","year":"2015","unstructured":"Serata D, Kotzalidis GD, Rapinesi C, Janiri D, Di Pietro S, Callovini G, et al. Are 5-HT3 antagonists effective in obsessive\u2013compulsive disorder? A systematic review of literature. Hum Psychopharmacology: Clin Experimental. 2015;30(2):70\u201384.","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"issue":"5","key":"610_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/YIC.0000000000000267","volume":"34","author":"M Sharafkhah","year":"2019","unstructured":"Sharafkhah M, Aghakarim Alamdar M, Massoudifar A, Abdolrazaghnejad A, Ebrahimi-Monfared M, Saber R, et al. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. Int Clin Psychopharmacol. 2019 Sep;34(5):222\u201333. PubMed PMID: 31058716. Epub 2019\/05\/07. eng.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"610_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1503\/jpn.160079","volume":"42","author":"T Bhikram","year":"2017","unstructured":"Bhikram T, Abi-Jaoude E, Sandor P. OCD: obsessive\u2013compulsive\u2026 disgust? The role of disgust in obsessive\u2013compulsive disorder. J psychiatry neuroscience: JPN. 2017;42(5):300.","journal-title":"J psychiatry neuroscience: JPN"},{"key":"610_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejphar.2013.09.072","volume":"722","author":"PL Andrews","year":"2014","unstructured":"Andrews PL, Sanger GJ. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol. 2014;722:108\u201321.","journal-title":"Eur J Pharmacol"},{"issue":"40","key":"610_CR22","doi-asserted-by":"publisher","first-page":"13709","DOI":"10.1523\/JNEUROSCI.2042-12.2012","volume":"32","author":"KJ Tuerke","year":"2012","unstructured":"Tuerke KJ, Limebeer CL, Fletcher PJ, Parker LA. Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT3 receptor in the posterior and anterior insular cortex. J Neurosci. 2012;32(40):13709\u201317.","journal-title":"J Neurosci"},{"issue":"1","key":"610_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1744-859X-9-39","volume":"9","author":"M Fornaro","year":"2010","unstructured":"Fornaro M, Martino M. Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report. Ann Gen Psychiatry. 2010;9(1):39.","journal-title":"Ann Gen Psychiatry"},{"issue":"186","key":"610_CR24","first-page":"163","volume":"30","author":"R Mohseni-Bandpey","year":"2020","unstructured":"Mohseni-Bandpey R, Moradi Chemeh F, Shalbafan M. Myoclonus as a Single Side Effect of Combination of Selective Serotonin Reuptake Inhibitors (SSRIs) and Clomipramine: Three Case Reports. J Mazandaran Univ Med Sci. 2020;30(186):163\u20139.","journal-title":"J Mazandaran Univ Med Sci"},{"key":"610_CR25","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th ed2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"11","key":"610_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The yale-brown obsessive compulsive scale: II. Validity Archives of general psychiatry. 1989;46(11):1012\u20136.","journal-title":"Validity Archives of general psychiatry"},{"issue":"11","key":"610_CR27","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006\u201311.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"610_CR28","first-page":"517","volume":"70","author":"S Esalatmanesh","year":"2016","unstructured":"Esalatmanesh S, Abrishami Z, Zeinoddini A, Rahiminejad F, Sadeghi M, Najarzadegan MR, et al. Minocycline combination therapy with fluvoxamine in moderate-to\u2010severe obsessive\u2013compulsive disorder: A placebo\u2010controlled, double\u2010blind, randomized trial. J Neuropsychiatry Clin Neurosci. 2016;70(11):517\u201326.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"610_CR29","doi-asserted-by":"crossref","unstructured":"Yousefzadeh F, Sahebolzamani E, Sadri A, Mortezaei A, Aqamolaei A, Mortazavi SH, et al. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. International Clinical Psychopharmacology. 2020.","DOI":"10.1097\/YIC.0000000000000321"},{"issue":"4\u20135","key":"610_CR30","first-page":"136","volume":"48","author":"M Shalbafan","year":"2015","unstructured":"Shalbafan M, Mohammadinejad P, Shariat S-V, Alavi K, Zeinoddini A, Salehi M, et al. Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: A double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2015;48(4\u20135):136\u201340.","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"610_CR31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","volume":"30","author":"S Pallanti","year":"2006","unstructured":"Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):400\u201312.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"610_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.psychres.2018.02.012","volume":"262","author":"A Ghajar","year":"2018","unstructured":"Ghajar A, Khoaie-Ardakani M-R, Shahmoradi Z, Alavi A-R, Afarideh M, Shalbafan M-R, et al. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Psychiatry Res. 2018;262:94\u2013101.","journal-title":"Psychiatry Res"},{"key":"610_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jad.2020.02.020","volume":"267","author":"B Araminia","year":"2020","unstructured":"Araminia B, Shalbafan M, Mortezaei A, Shirazi E, Ghaffari S, Sahebolzamani E, et al. L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Affect Disord. 2020;267:131\u20136.","journal-title":"J Affect Disord"},{"key":"610_CR34","doi-asserted-by":"crossref","unstructured":"Ghaffari S, Ghobadi A, Jamshidi AH, Mortazavi SH, Naderi S, Aqamolaei A, et al. Cinnamomum tamala as an adjuvant therapy in the treatment of major depressive disorder: A double-blind, randomized, placebo-controlled clinical trial with placebo control. Advances in Integrative Medicine. 2019.","DOI":"10.1016\/j.aimed.2019.12.002"},{"issue":"3","key":"610_CR35","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1124\/jpet.106.112607","volume":"321","author":"ZA Rodd","year":"2007","unstructured":"Rodd ZA, Gryszowka VE, Toalston JE, Oster SM, Ji D, Bell RL, et al. The reinforcing actions of a serotonin-3 receptor agonist within the ventral tegmental area: evidence for subregional and genetic differences and involvement of dopamine neurons. J Pharmacol Exp Ther. 2007;321(3):1003\u201312.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"610_CR36","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.biopsych.2010.12.003","volume":"69","author":"M Figee","year":"2011","unstructured":"Figee M, Vink M, de Geus F, Vulink N, Veltman DJ, Westenberg H, et al. Dysfunctional reward circuitry in obsessive-compulsive disorder. Biol Psychiatry. 2011;69(9):867\u201374.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"610_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0149-7634(99)00067-6","volume":"23","author":"A Meneses","year":"1999","unstructured":"Meneses A. 5-HT system and cognition. Neurosci Biobehavioral Reviews. 1999;23(8):1111\u201325.","journal-title":"Neurosci Biobehavioral Reviews"},{"issue":"3","key":"610_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","volume":"51","author":"SM Stahl","year":"1998","unstructured":"Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215\u201335.","journal-title":"J Affect Disord"},{"issue":"7","key":"610_CR39","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/sj.mp.4001823","volume":"11","author":"M Bloch","year":"2006","unstructured":"Bloch M, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken M, Leckman J. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622\u201332.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"610_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1017\/S1461145712000740","volume":"16","author":"M Dold","year":"2013","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16(3):557\u201374.","journal-title":"Int J Neuropsychopharmacol"},{"key":"610_CR41","doi-asserted-by":"crossref","unstructured":"Hadi F, Kashefinejad S, Kamalzadeh L, Hoobehfekr S, Shalbafan M. Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis. BMC Pharmacology and Toxicology. 2021 2021\/11\/04;22(1):69.","DOI":"10.1186\/s40360-021-00534-6"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-022-00610-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T18:08:42Z","timestamp":1664302122000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-022-00610-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1186\/s40360-022-00610-5","relation":{},"ISSN":["2050-6511"],"issn-type":[{"type":"electronic","value":"2050-6511"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by the ethics committee of Iran University of Medical Sciences institutional review board (IRB: IR.IUMS.REC.1398.060, grant number: 97-4-23-13222) and conducted according to the Declaration of Helsinki and subsequent revisions. Informed consent was obtained from all subjects and their legal guardian(s). Patients were informed that the nature of their participation was a voluntary activity and that they had the right to leave the trial at any time with no negative effect regarding their treatment. The trial was registered at the Iranian Registry of Clinical Trials (; IRCT ID: IRCT20170123032145N3).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}